SENS-IT-IV Framework 6 EU Grant Award

8th May 2008

COBHAM, England – Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has been selected to participate as a partner in the 13.7m euro Sens-it-iv Framework 6 EU programme, the largest Integrated Project in the EU funding programme, the aim of which is to develop 'in-vitro' alternatives to animal tests currently used for the risk assessment of potential skin or lung conditions.

Worldwide, the occurrence of allergies is increasing and has become an important health problem. In the EU, no 'in-vitro' tests or strategies are yet available to test the potential of chemical compounds or substances to induce allergies. By 2009, elements of products that come into contact with skin or the respiratory system (intentionally or unintentionally) have to be tested under EU law. Without the approved test disclosure, products will not be able to be sold in the EU.

Proteome Sciences is undertaking the proteomics part of the Sens-it-iv project and has been awarded a grant of 571,000 euros over the period to 2010. This is an important programme supported by the EU to improve safety for the consumer and the environment and also to achieve a reduction in the levels of animal testing. The consortium is made up from 32 members, largely academic, other than five SMEs and two major commercial partners, L'Oreal and Unilever.

Further details of Sens-it-iv can be found at: http://www.sens-it-iv.eu.

Christopher Pearce, CEO of Proteome Sciences commented:

"The goal of Sens-it-iv is to replace animal experimentation by in-vitro assays for skin and respiratory responses in relation to the use of safe ingredients by the chemical, cosmetic and pharmaceutical industries, to comply with the new EU legislation for classification and labeling of chemicals and risk assessment.

From 2009, before any such ingredients can be brought into the EU, they must have first been evaluated for their safety for humans and the environment. This requirement will have a considerable impact across a diverse range of industries and products. Proteome Sciences is delighted to be undertaking the proteomics aspects of this key programme to develop a new generation of in-vitro assays and to address the social and economic impact for skin and respiratory conditions and we will also participate in commercial value that arises from the project."